G
Garret A. FitzGerald
Researcher at University of Pennsylvania
Publications - 573
Citations - 64984
Garret A. FitzGerald is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Prostacyclin & Thromboxane. The author has an hindex of 127, co-authored 547 publications receiving 60448 citations. Previous affiliations of Garret A. FitzGerald include French Institute of Health and Medical Research & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.
TL;DR: It seems reasonable that PGI2 and TxA2 might play an important role in this and other syndromes of disordered platelet-vascular homeostasis in man, and support for this concept relies upon the development of methods to measure PGI 2 and TXA2 in human biological fluids.
Journal ArticleDOI
Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation.
TL;DR: Prostacyclin production may be low in healthy persons because there is almost no stimulus for its production but enhanced in patients with severe atherosclerosis as a consequence of platelet interactions with endothelium or other vascular insults, which is compatible with a role for prostacyClin as a local regulator of Platelet-vascular interactions.
Journal ArticleDOI
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
TL;DR: The role of COX-2 inhibitors in a number of indications, including cardiovascular disease, hypertension and atherosclerosis are reviewed.
Journal ArticleDOI
Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles.
TL;DR: A novel mechanism of transcellular lipid metabolism whereby platelet activation may be amplified or modulated by concentrated delivery of arachidonic acid to adjacent platelets and endothelial cells is indicated.
Journal ArticleDOI
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Christopher P. Cannon,Sean P. Curtis,Garret A. FitzGerald,Henry Krum,Amarjot Kaur,James A. Bolognese,Alise S. Reicin,Claire Bombardier,Michael E. Weinblatt,Désirée van der Heijde,Erland Erdmann,Loren Laine +11 more
TL;DR: Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs.